According to a story from Business Wire, the biotechnology company Viridian Therapeutics, Inc., has completed its enrollment goal for its phase 3 clinical trial designated THRIVE-2. This clinical trial will evaluate the organization’s investigational therapy VRDN-001 as a treatment for people living with chronic thyroid eye disease. Viridian is focused on best-in-class therapeutics for rare disease and serious diseases.
While the enrollment target for this trial was 159 patients, this goal was actually exceeded and a total of 188 patients have been registered. Around 40% of participants are based in the US. The company anticipates having topline data from the study by the end of the year. The exceeding of the target enrollment was primarily the result of patient demand.
About VRDN-001
As the lead candidate for Viridian, VRDN-001 is classified as a monoclonal antibody which is an antagonist of insulin-like growth factor-1 receptor (IGF-1R), which is considered a validated therapeutic target in the treatment of thyroid eye disease. This therapy is delivered intravenously and has the potential to offer advantages over currently available therapies targeting IGF-1R, such as reduced number of infusions and shorter duration of infusions.
About Thyroid Eye Disease
Thyroid eye disease, which is also known as Graves’ ophthalmopathy, is an inflammatory disorder affecting the eyes and the surrounding tissues. The disease is autoimmune in nature and most common appears alongside Graves’ disease, an autoimmune illness that affects the thyroid. Hyperthyroidism is a significant risk factor. It can also appear in patients with Hashimoto’s thyroiditis. Women are more likely to be affected than men, but men tend to be affected at older ages and have worse prognosis. It can also appear on its own without comorbidity. Symptoms of thyroid eye disease include lid lag, upper eyelid retraction, eye bulging, swelling, eye inflammation, and redness around the eyes. Severe cases, while rare, are a medical emergency that can threaten vision and inflict severe pain. In mild cases thyroid eye disease may eventually resolve on its own. Treatment may include corticosteroids, surgery, topical lubrication, and selenium supplementation. To learn more about the disease, click here.
